A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab (MK-3475) as Monotherapy in the Adjuva

Clinical Trial Details

MK-3475-KEYNOTE-564 USOR 16251

A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (KEYNOTE-564)

Purpose/Objective

Request Additional Trial Information
Full Trial Details: ClinicalTrials.gov

Condition: Renal Cancer
Study Type: Interventional
Phase: Phase III
Study Start Date: 07/20/18
Study Completion Date: 12/2025

Safety and Efficacy Study of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy, RCC Clear Cell Component

NCT Number
NCT03142334
Principal Investigator(s)
Manish Agarwal, MD
Sponsor(s)
Merck Sharp & Dohme Corp
Participant Eligibility
  • Age: 18 - No Maximum
  • Gender: Male, Female

Location

  • Shady Grove Adventist Aquilino Cancer Center
    9905 Medical Center Drive
    Rockville, MD 20850
    Main: 240-826-6297

Find a Doctor

Find an Adventist HealthCare affiliated doctor by calling our FREE physician referral service at 800-642-0101 or by searching our online physician directory.

View Doctors

Set Your Location

Setting your location helps us to show you nearby providers and locations based on your healthcare needs.